<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023516</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00020</org_study_id>
    <nct_id>NCT01023516</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol</brief_title>
  <official_title>A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in
      symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Pre-bronchodilator FEV1 (L)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End-value Pre-bronchodilator FEV1 (L)</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1 (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1 (L) - End-value</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FVC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced vital capacity (FVC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FVC (L) - End-value</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FVC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced vital capacity (FVC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FVC (L) - End-value</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pre-bronchodilator FEV6 (L)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-value Pre-bronchodilator FEV6 (L)</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Post-bronchodilator FEV6 (L)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured post after bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-value Post-bronchodilator FEV6 (L)</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pre-bronchodilator FEF25-75% (L/Sec)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-value Pre-bronchodilator FEF25-75% (L/Sec)</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Post-bronchodilator FEF25-75% (L/Sec)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-value Post-bronchodilator FEF25-75% (L/Sec)</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator IC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Inspiratory capacity (IC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator IC (L) - End-value</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator IC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Inspiratory capacity (IC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator IC (L) - End-value</measure>
    <time_frame>up to week 12</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</measure>
    <time_frame>Baseline</time_frame>
    <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Peak expiratory flow (PEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</measure>
    <time_frame>Baseline</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 - End-value Measured by Patient at Home (L) in the Morning</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Forced Expiratory Volume in 1 second (L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXACT - Baseline Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXACT - End-value Total Score</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCSS - Baseline Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCSS - End-value Total Score</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Colour - Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Colour - End Value</measure>
    <time_frame>End of treatment week 12</time_frame>
    <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status). End of treatment week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Daily average of number of inhalations of reliever medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Shuttle Walk Test - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Endurance time (s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Shuttle Walk Test - End Value</measure>
    <time_frame>Week 12 - visit 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance Shuttle Walk Test - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Endurance time (s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance Shuttle Walk Test - End Value</measure>
    <time_frame>Week 12 - visit 6</time_frame>
    <description>Assessed at vist 6 -( last on treatment clinic visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</measure>
    <time_frame>Measured Day 1 and 12 weeks</time_frame>
    <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).Questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations - Clinic Defined</measure>
    <time_frame>Duration of the the treatment period - 12 weeks</time_frame>
    <description>Number of patients having a clinic defined disease exacerbation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>2 x 30 mg oral tablets bd for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 x matched placebo to oral tablet bd for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD with symptoms over 1 year

          -  FEV1/FVC &lt; 70% and FEV1 &gt;= 30 and &lt; 80 % of predicted post-bronchodilator

          -  Symptomatic COPD for a total of 7 days in the two weeks prior to randomisation

          -  At least 1 COPD exacerbation from 4 weeks to 12 months before the screening visit

        Exclusion Criteria:

          -  Past history or current evidence of clinically significant heart disease

          -  Current diagnosis of asthma

          -  Patients who require long term oxygen therapy

          -  Worsening of COPD requiring treatment with antibiotics, an increase in inhaled steroid
             dose and/or oral steroids within 4 weeks of study visit 1b
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samodzielny Publiczny ZOZ Uniwersytecki Szpital Kliniczny</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lovech</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Russe</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krnov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novy Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trebic</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torokbalint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vasarosnameny</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzow Wlkp</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jelenia Gora</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pila</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deva</city>
        <state>Hunedoara</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bojnice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunajska Streda</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Humenne</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Mesto Nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Revuca</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trstena</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>January 24, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2012</results_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>obstructive</keyword>
  <keyword>pulmonary</keyword>
  <keyword>lung</keyword>
  <keyword>respiratory disease</keyword>
  <keyword>efficacy</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>COPD</keyword>
  <keyword>FEV1</keyword>
  <keyword>St Georges Respiratory Questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 24 November 2009. Last patient completed 18 August 2010. Study conducted at 79 centres in 6 countries (Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovakia).</recruitment_details>
      <pre_assignment_details>3- or 4-week run-in period on budesonide/formoterol twice daily to stabilise patients on maintenance therapy before randomisation. Patients already on budesonide/formoterol required a 3-week run-in period and patients on ICS as monotherapy or in combination with any long-acting bronchodilator required a 4-week run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntary discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="313"/>
            <count group_id="B2" value="302"/>
            <count group_id="B3" value="615"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="42" upper_limit="80"/>
                    <measurement group_id="B2" value="61" lower_limit="41" upper_limit="79"/>
                    <measurement group_id="B3" value="61.5" lower_limit="41" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Pre-bronchodilator FEV1 (L)</title>
        <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pre-bronchodilator FEV1 (L)</title>
          <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.539"/>
                    <measurement group_id="O2" value="1.44" spread="0.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>End-value Pre-bronchodilator FEV1 (L)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Pre-bronchodilator FEV1 (L)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.015" lower_limit="0.015"/>
                    <measurement group_id="O2" value="1.43" spread="0.015" lower_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1 (L) - Baseline</title>
        <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1 (L) - Baseline</title>
          <description>Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.530"/>
                    <measurement group_id="O2" value="1.56" spread="0.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1 (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1 (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.014" lower_limit="0.014"/>
                    <measurement group_id="O2" value="1.54" spread="0.015" lower_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FVC (L) - Baseline</title>
        <description>Forced vital capacity (FVC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FVC (L) - Baseline</title>
          <description>Forced vital capacity (FVC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.781"/>
                    <measurement group_id="O2" value="2.94" spread="0.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FVC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FVC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.022" lower_limit="0.022"/>
                    <measurement group_id="O2" value="2.93" spread="0.022" lower_limit="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FVC (L) - Baseline</title>
        <description>Forced vital capacity (FVC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FVC (L) - Baseline</title>
          <description>Forced vital capacity (FVC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.787"/>
                    <measurement group_id="O2" value="3.12" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FVC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FVC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="0.021" lower_limit="0.021"/>
                    <measurement group_id="O2" value="3.11" spread="0.021" lower_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pre-bronchodilator FEV6 (L)</title>
        <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pre-bronchodilator FEV6 (L)</title>
          <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.729"/>
                    <measurement group_id="O2" value="2.61" spread="0.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-value Pre-bronchodilator FEV6 (L)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Pre-bronchodilator FEV6 (L)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="0.019" lower_limit="0.019"/>
                    <measurement group_id="O2" value="2.61" spread="0.019" lower_limit="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Post-bronchodilator FEV6 (L)</title>
        <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured post after bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Post-bronchodilator FEV6 (L)</title>
          <description>Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured post after bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.724"/>
                    <measurement group_id="O2" value="2.79" spread="0.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-value Post-bronchodilator FEV6 (L)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Post-bronchodilator FEV6 (L)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.017" lower_limit="0.017"/>
                    <measurement group_id="O2" value="2.78" spread="0.018" lower_limit="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pre-bronchodilator FEF25-75% (L/Sec)</title>
        <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pre-bronchodilator FEF25-75% (L/Sec)</title>
          <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.380"/>
                    <measurement group_id="O2" value="0.55" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-value Pre-bronchodilator FEF25-75% (L/Sec)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Pre-bronchodilator FEF25-75% (L/Sec)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.016" lower_limit="0.016"/>
                    <measurement group_id="O2" value="0.56" spread="0.016" lower_limit="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Post-bronchodilator FEF25-75% (L/Sec)</title>
        <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Post-bronchodilator FEF25-75% (L/Sec)</title>
          <description>Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.367"/>
                    <measurement group_id="O2" value="0.60" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-value Post-bronchodilator FEF25-75% (L/Sec)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Post-bronchodilator FEF25-75% (L/Sec)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.016" lower_limit="0.016"/>
                    <measurement group_id="O2" value="0.61" spread="0.016" lower_limit="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator IC (L) - Baseline</title>
        <description>Inspiratory capacity (IC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator IC (L) - Baseline</title>
          <description>Inspiratory capacity (IC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.661"/>
                    <measurement group_id="O2" value="2.17" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator IC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator IC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="0.024" lower_limit="0.024"/>
                    <measurement group_id="O2" value="2.14" spread="0.025" lower_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator IC (L) - Baseline</title>
        <description>Inspiratory capacity (IC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator IC (L) - Baseline</title>
          <description>Inspiratory capacity (IC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.718"/>
                    <measurement group_id="O2" value="2.30" spread="0.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator IC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>up to week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator IC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.023" lower_limit="0.023"/>
                    <measurement group_id="O2" value="2.27" spread="0.023" lower_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</title>
        <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</title>
          <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.60" spread="98.406"/>
                    <measurement group_id="O2" value="213.24" spread="96.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</title>
        <description>Peak expiratory flow (PEF)</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</title>
          <description>Peak expiratory flow (PEF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.68" spread="2.153" lower_limit="2.153"/>
                    <measurement group_id="O2" value="211.93" spread="2.189" lower_limit="2.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.546"/>
                    <measurement group_id="O2" value="1.34" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 - End-value Measured by Patient at Home (L) in the Morning</title>
        <description>Forced Expiratory Volume in 1 second (L)</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 - End-value Measured by Patient at Home (L) in the Morning</title>
          <description>Forced Expiratory Volume in 1 second (L)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.012" lower_limit="0.012"/>
                    <measurement group_id="O2" value="1.32" spread="0.012" lower_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXACT - Baseline Total Score</title>
        <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>EXACT - Baseline Total Score</title>
          <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.47" spread="9.683"/>
                    <measurement group_id="O2" value="46.01" spread="8.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXACT - End-value Total Score</title>
        <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>EXACT - End-value Total Score</title>
          <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.78" spread="0.473" lower_limit="0.473"/>
                    <measurement group_id="O2" value="43.07" spread="0.480" lower_limit="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCSS - Baseline Total Score</title>
        <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>BCSS - Baseline Total Score</title>
          <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="1.787"/>
                    <measurement group_id="O2" value="5.44" spread="1.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCSS - End-value Total Score</title>
        <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>BCSS - End-value Total Score</title>
          <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="0.085" lower_limit="0.085"/>
                    <measurement group_id="O2" value="4.68" spread="0.086" lower_limit="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Colour - Baseline</title>
        <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Colour - Baseline</title>
          <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.901"/>
                    <measurement group_id="O2" value="1.88" spread="0.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Colour - End Value</title>
        <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status). End of treatment week 12</description>
        <time_frame>End of treatment week 12</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Colour - End Value</title>
          <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status). End of treatment week 12</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.042" lower_limit="0.042"/>
                    <measurement group_id="O2" value="1.70" spread="0.042" lower_limit="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication</title>
        <description>Daily average of number of inhalations of reliever medication</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication</title>
          <description>Daily average of number of inhalations of reliever medication</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>inhalations</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="0.124" lower_limit="0.124"/>
                    <measurement group_id="O2" value="3.37" spread="0.126" lower_limit="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Shuttle Walk Test - Baseline</title>
        <description>Endurance time (s)</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Shuttle Walk Test - Baseline</title>
          <description>Endurance time (s)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351" spread="119.5"/>
                    <measurement group_id="O2" value="352" spread="108.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Shuttle Walk Test - End Value</title>
        <time_frame>Week 12 - visit 6</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Shuttle Walk Test - End Value</title>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.6" spread="3.39" lower_limit="3.39"/>
                    <measurement group_id="O2" value="363.7" spread="3.44" lower_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endurance Shuttle Walk Test - Baseline</title>
        <description>Endurance time (s)</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Endurance Shuttle Walk Test - Baseline</title>
          <description>Endurance time (s)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419" spread="269.4"/>
                    <measurement group_id="O2" value="449" spread="292.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endurance Shuttle Walk Test - End Value</title>
        <description>Assessed at vist 6 -( last on treatment clinic visit)</description>
        <time_frame>Week 12 - visit 6</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Endurance Shuttle Walk Test - End Value</title>
          <description>Assessed at vist 6 -( last on treatment clinic visit)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.6" spread="10.49" lower_limit="10.49"/>
                    <measurement group_id="O2" value="459.9" spread="10.68" lower_limit="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</title>
        <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</title>
          <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.52" spread="16.863"/>
                    <measurement group_id="O2" value="54.87" spread="17.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</title>
        <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).Questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
        <time_frame>Measured Day 1 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</title>
          <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).Questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.89" spread="0.777" lower_limit="0.777"/>
                    <measurement group_id="O2" value="50.66" spread="0.796" lower_limit="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations - Clinic Defined</title>
        <description>Number of patients having a clinic defined disease exacerbation.</description>
        <time_frame>Duration of the the treatment period - 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations - Clinic Defined</title>
          <description>Number of patients having a clinic defined disease exacerbation.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

